Supportive evidence for *FOXP1*, *BARX1*, and *FOXF1* as genetic risk loci for the development of esophageal adenocarcinoma

Jessica Becker¹,², Andrea May³, Christian Gerges⁴, Mario Anders⁵,⁶, Lothar Veits⁷, Katharina Weise¹,², Darina Czamara⁸, Orestis Lyros⁹, Hendrik Manner¹⁰, Grischa Terheggen⁴, Marino Venerito¹¹, Tania Noder⁵, Rupert Mayerhofer¹², Jan-Hinnerk Hofer¹³, Hans-Werner Karch¹⁴, Constantin J. Ahlbrand¹⁵, Michael Arras¹⁵, Sebastian Hofer¹⁵, Elisabeth Mangold¹,², Stefanie Heilmann-Heimbach¹,², Sophie K. M. Heinrichs¹,², Timo Hess¹,², Ralf Kiesslich¹⁰, Jakob R. Izbički¹⁶, Arnulf H. Hölscher¹⁷, Elfriede Bollschweiler¹⁷, Peter Malfertheiner¹¹, Hauke Lang¹⁵, Markus Moeher¹⁸, Dietmar Lorenz¹⁹, Bertram Müller-Myhosk⁸, Katja Ott²⁰,²¹, Thomas Schmidt²¹, David C. Whiteman²², Thomas L. Vaughan²³,²⁴, Markus M. Nöthen¹,², Andreas Hackelsberger²⁵, Brigitte Schumacher⁴,²⁶, Oliver Pech²⁷, Yogesh Vashist¹⁶, Michael Vieth⁷, Josef Weismüller²⁸, Horst Neuhaus⁴, Thomas Rösch⁵, Christian Ell¹³, Ines Gockel⁹,¹⁵,²⁸ & Johannes Schumacher¹,²,a

¹Institute of Human Genetics, University of Bonn, Bonn, Germany
²Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany
³Department of Medicine II, Sana Klinikum, Offenbach, Germany
⁴Department of Internal Medicine II, Evangelisches Krankenhaus, Düsseldorf, Germany
⁵Department of Interdisciplinary Endoscopy, University Hospital Hamburg-Eppendorf, Hamburg, Germany
⁶Department of Gastroenterology and Interdisciplinary Endoscopy, Vivantes Wenzkebach-Klinikum, Berlin, Germany
⁷Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany
⁸Statistical Genetics, Max Planck Institute of Psychiatry, Munich, Germany
⁹Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig, Leipzig, Germany
¹⁰Department of Internal Medicine II, HSK Hospital, Wiesbaden, Germany
¹¹Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Magdeburg, Germany
¹²Gastroenterologie am Burgweiler, Bonn, Germany
¹³Magen Darm Zentrum Wiener Platz, Cologne, Germany
¹⁴Gastroenterologische Schwerpunktpraxis, Baumholder, Germany
¹⁵Department of General, Visceral and Transplant Surgery, University Medical Center, University of Mainz, Mainz, Germany
¹⁶Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany
¹⁷Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany
¹⁸First Department of Internal Medicine, University Medical Center, University of Mainz, Mainz, Germany
¹⁹Department of General and Visceral Surgery, Sana Klinikum, Offenbach, Germany
²⁰Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany
²¹Department of General, Visceral and Thorax Surgery, RoMed Klinikum Rosenheim, Rosenheim, Germany
²²Cancer Control, QIMR Berghofer Medical Research Institute, Brisbane, Australia
²³Department of Epidemiology, University of Washington, School of Public Health, Seattle, Washington
²⁴Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
²⁵Gastropraxis, Wiesbaden, Germany
²⁶Department of Internal Medicine and Gastroenterology, Elisabeth Hospital, Essen, Germany
²⁷Department of Gastroenterology and Interventional Endoscopy, St. John of God Hospital, Regensburg, Germany
²⁸Gastroenterologische Gemeinschaftspraxis, Koblenz, Germany

**Keywords**

*BARX1*, esophageal adenocarcinoma, *FOXF1*, *FOXP1*, genetic association study

**Abstract**

The Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) recently performed a genome-wide association study (GWAS) on esophageal adenocarcinoma (EAC) and Barrett’s esophagus. They identified genome-wide significant association for variants at three genes, namely *CRTC1*, *FOXP1*, and *BARX1*. Furthermore, they replicated an association at the *FOXP1* gene that has been previously found in a GWAS on Barrett’s esophagus. We aimed at further replicating the association at these and other loci that showed suggestive
and performed a stepwise conditional analysis to test for associated SNP marker in their discovery sample, rs3950627, chromosome 16q24. They used the most significant as-

**FOXF1** (forkhead box F1) gene on reported association with Barrett’s esophagus [6] near the cancer [4, 5].

**FOXP1**, which encodes a transcription factor regulat-

**BARX1** (homeobox protein BarH-like 1b) in intron 3 of the gene most significant associated marker, rs11789015, is located chromosome 3p13 (top SNP marker rs2687201). The near-

**CRTC1**, whose aberrant activation has been associated with oncogenic activity [2]. The second locus concerns chromosome 9q22 and the most significant associated marker, rs11789015, is located in intron 3 of the gene **homeobox protein BarH-like 1b** (BARXI), which encodes a transcription factor important in esophageal differentiation [3]. The third locus is on chromosome 3p13 (top SNP marker rs2687201). The nearest gene to this association signal is **CREB-regulated transcription coactivator (CRTC1)**, whose aberrant activation has been associated with oncogenic activity [2].

The second locus concerns chromosome 9q22 and the most significant associated marker, rs11789015, is located in intron 3 of the gene **homeobox protein BarH-like 1b** (BARXI), which encodes a transcription factor important in esophageal differentiation [3]. The third locus is on chromosome 3p13 (top SNP marker rs2687201). The nearest gene to this association signal is **forkhead box protein P1** (FOXP1), which encodes a transcription factor regulating esophageus development and acts as therapeutic target in cancer [4, 5].

Furthermore, the BEACON study refined a previously reported association with Barrett’s esophagus [6] near the transcription factor **forkhead box F1** (FOXF1) gene on chromosome 16q24. They used the most significant associated SNP marker in their discovery sample, rs3950627, and performed a stepwise conditional analysis to test for independent SNP associations within this region. In total, they identified three additional association signals (at rs1490865, rs3111601, and rs2178146) pointing to a complex genetic risk architecture at 16q24. The association of the originally reported risk conferring SNP, rs9936833, was thereby explained by all four SNP markers that showed association in the stepwise conditional analysis.

In the present study, we aimed at further replicating the associations obtained by BEACON. We genotyped all 87 SNP markers in an independent German sample of 1065 EAC cases and 1019 controls that showed association with \( P < 10^{-4} \) to EAC/Barrett’s esophagus in the replication study.

### Introduction

Recently, the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) presented their genome-wide association study (GWAS) on 1516 cases with esophageal adenocarcinoma (EAC), 2416 cases with nonneoplastic Barrett’s esophagus, and 3209 healthy individuals (discovery sample), all of European ancestry [1]. For the case–control analysis both disease conditions were considered as one single phenotype (total of 3932 cases). Eighty-seven single nucleotide polymorphisms (SNPs) showed disease association with \( P < 10^{-4} \) and were followed up in 874 EAC and 759 Barrett’s esophagus cases (total of 1633 cases) as well as 6911 controls from the United Kingdom (replicition sample). In total, SNPs at three different loci showed genome-wide significant disease association in the combined sample. The first is on chromosome 19p13 (top SNP marker rs10419226) containing the gene **CREB-regulated transcription coactivator (CRTC1)**, whose aberrant activation has been associated with oncogenic activity [2].

**Material and Methods**

Our sample consisted of 1065 EAC cases and 1019 controls, all of German descent. In all cases the diagnosis of EAC was histopathologically confirmed. Controls were a population-based sample recruited among voluntary blood donors at the University of Bonn. All participants signed informed consent and the study was approved by ethics committees from the Universities of Mainz and Bonn (Germany). Although none of the controls had been diagnosed with EAC, they have not been screened regarding Barrett’s esophagus status. In all, 127 cases were females and 938 were males. In controls, 521 were females and 498 were males. Of note, due to the small size of the female sample our statistical power was only moderate to detect sex-specific risk variants. Genotyping of all 90 markers was done using the Sequenom MassARRAY iPLEX Gold® system
(Sequenom, San Diego, CA). For quality control we genotyped intra- and interplate duplicates. In addition, we added negative controls (H₂O) on each 384-well plate to exclude contamination. Clusterplot of each SNP was visually checked and manually corrected if necessary. Genotyping data underwent different quality control steps (Hardy–Weinberg equilibrium \( P > 0.001 \), call rate > 95%). After applying these criteria, 88 SNPs remained for association testing (see Table S1). Single marker association analyses including sex as covariate were performed in the whole sample set and in addition sex specifically (i.e., females and males, separately). Quality control as well as single marker association analysis were carried out using PLINK software [7].

Results

After quality control, 88 of 90 SNPs were tested for association with EAC. None of the tested variants showed EAC association in our case–control sample after Bonferroni correction \((P < 5.68 \times 10^{-4}, \text{Table S1})\). However, eight SNPs reached nominal significance \((P < 0.05)\) and 11 SNPs were EAC associated when one-sided tested \( (P_{1-\text{d.f.}} < 0.05, \text{Table S1}) \). Of these markers, 11 showed association with the same allelic direction as reported previously in the GWAS samples \((\text{Table 1})\). The most significant EAC association in our sample was found for rs2687201 followed by rs9837992 \( (P_{1-\text{d.f.}} = 0.0007 \text{ and } P_{1-\text{d.f.}} = 0.002, \text{respectively, Table 1}) \). Both variants are located at the same chromosomal locus 3p13 containing FOXPI that has been identified with genome-wide significant association in the BEACON study \([1]\). The association was more pronounced in male compared to female cases \( (e.g. P_{1-\text{d.f.male}} = 0.0004 \text{ and } P_{1-\text{d.f.female}} = 0.310 \text{ for rs2687201, Table 1}) \). Furthermore, two of the previously highlighted GWAS variants also showed EAC association in our sample with the same alleles being risk conferring \((\text{Table 1})\). SNP rs11789015 is located in intron 3 of BARX1 on chromosome 9q22 and was genome-wide significantly associated with the BEACON sample \([1]\). This variant showed also EAC association in our sample \( (P_{1-\text{d.f.}} = 0.044) \), which was more pronounced in female compared to male cases \( (P_{1-\text{d.f.male}} = 0.267 \text{ and } P_{1-\text{d.f.female}} = 0.010, \text{Table 1}) \). In addition, rs9936833, which was genome-wide significantly associated with the Barrett’s esophagus GWAS \([6]\) and is located near FOXF1 on chromosome 16q24, was EAC associated \( (P_{1-\text{d.f.}} = 0.045, \text{Table 1}) \). In addition, two of the remaining SNPs with EAC association in our sample \( (\text{Table 1}) \) are of particular interest, as they show disease association in both BEACON samples, the discovery and the replication cohort. SNP rs11771429 is located nearby the gene XRCC2 encoding for a DNA repair protein and showed EAC association in our sample with \( P_{1-\text{d.f.}} = 0.042 \) \((\text{Table 1})\). In addition, rs4800353 near the gene GATA-binding protein 6 \((\text{GATA6})\) was EAC associated with our sample \( (P_{1-\text{d.f.}} = 0.034, \text{Table 1}) \). Finally, we compared the genetic effect sizes at all five implicated loci \((\text{FOXPI, BARX1, FOXF1, XRCC2, and GATA6})\) between our and the BEACON study and observed that they are all in the same range \((\text{Fig. S1, and Table S1})\).

Discussion

In the present study, we aimed at replicating associations to EAC/Barrett’s esophagus which have been previously reported in the BEACON GWAS \([1]\). We tested 85 SNP markers that yielded \( P < 10^{-4} \) in their GWAS discovery sample in our sample of 1065 cases with EAC and 1019 controls, all of German descent. In addition, three SNPs near FOXF1 \( (\text{in total eight SNPs}) \) that have been highlighted in the BEACON study and in another GWAS on Barrett’s esophagus \([6]\) were genotyped. Of all 88 included variants, we found the most significantly EAC-associated SNPs at FOXPI, which were also genome-wide significantly associated with EAC/Barrett’s esophagus in the BEACON study. Although our findings do not withstand a Bonferroni correction, they confirm that genetic variability at FOXPI confers risk to EAC. Furthermore, our study supports the involvement of two previously reported risk loci in the EAC pathology. When one-sided tested, variants at BARX1 and FOXF1 showed disease association. However, given that rs3950627, which was the strongest associated SNP at FOXF1 in the BEACON study \([1]\) showed no significant EAC association in our sample \( (P = 0.121, \text{Table S1}) \), we did not perform a conditional analysis at this locus, as has been done by BEACON. Thus, our study does not provide any further information about the genetic EAC risk architecture at this locus. Furthermore, of all previously reported risk loci we do not find association evidence for CRTC1 \( (P = 0.349 \text{ for rs10419226, Table S1}) \), which was the strongest associated SNP at FOXF1 in the BEACON study \([1]\) showed no significant EAC association in our sample \( (P = 0.121, \text{Table S1}) \), we did not perform a conditional analysis at this locus, as has been done by BEACON. Thus, our study does not provide any further information about the genetic EAC risk architecture at this locus. Furthermore, of all previously reported risk loci we do not find association evidence for CRTC1 \( (P = 0.349 \text{ for rs10419226, Table S1}) \), which was the strongest associated SNP at FOXF1 in the BEACON study \([1]\) showed no significant EAC association in our sample. One explanation for the failed replication might be limited statistical power of our study sample and/or that the risk effect at this locus has been overestimated in the initial GWAS, a phenomenon that is called the “winner’s curse”. Hereby, CRTC1 represents a true risk locus, but the observed effect size in the initial study is randomly higher than the true effect size. Also other factors might be responsible for the observed differences between the BEACON GWAS and our replication study. In comparison to the GWAS sample, our replication cohort is smaller and therefore the statistical power of the present study is limited. Furthermore, the use of population-based controls instead of controls screened for Barrett’s esophagus may have led
to an additional power loss. However, two SNPs that were replicated in the BEACON replication cohort and showed strong but not genome-wide significant association ($P < 10^{-5}$) in the combined GWAS sample (discovery and replication cohort) showed EAC association within this study. SNP rs11771429 is located nearby XRCC2 and showed disease association in the BEACON study with $P = 8.40 \times 10^{-6}$ [1]. The corresponding protein represents a member of the RAD51 family and thereby plays a pivotal role in DNA repair and carcinogenesis [8]. In addition, rs4800353 near GATA6 showed disease association in the BEACON study with $P = 2.69 \times 10^{-7}$ [1]. Also, GATA6 represents a plausible EAC candidate gene as it encodes a transcription factor with an important role in the regulation of cellular differentiation. Of note, GATA6 has already been implicated in the development of EAC [9–11]. However, although CRC2 and GATA6 represent interesting candidate genes, independent replications at these loci are needed before adding the respective SNPs to the list of confirmed EAC risk variants.

### Table 1. Association results for all replicated SNPs in 1065 EAC cases and 1019 controls of German descent.

| SNP       | Chr: Pos | Allele | Group | MAF in % | OR (95% CI) | $P_{2-d.f.}$ | $P_{1-d.f.}$ | Nearby genes       |
|-----------|----------|--------|-------|----------|-------------|-------------|-------------|-------------------|
| rs17030152| 1: 7083719 | C/T    | All   | 25.5     | 0.87 (0.75–1.01) | 0.068       | 0.034       | THAP3, DNAJC11, CAMTA1 |
|           |          |        | M     | 25.6     | 0.89 (0.75–1.06) | 0.190       | 0.095       |                   |
|           |          |        | F     | 24.4     | 0.80 (0.59–1.10) | 0.167       | 0.083       |                   |
| rs2687201 | 3: 70928930 | A/C   | All   | 36.0     | 1.26 (1.09–1.46) | 0.0014      | 0.0007      | MITF, FOXP1, EIF4E3 |
|           |          |        | M     | 36.4     | 1.33 (1.13–1.57) | 0.0007      | 0.0004      |                   |
|           |          |        | F     | 32.8     | 1.08 (0.81–1.43) | 0.620       | 0.310       |                   |
| rs9837992 | 3: 70959438 | A/G   | All   | 35.5     | 1.23 (1.07–1.42) | 0.005       | 0.002       | MITF, FOXP1, EIF4E3 |
|           |          |        | M     | 35.7     | 1.30 (1.10–1.54) | 0.002       | 0.001       |                   |
|           |          |        | F     | 33.9     | 1.04 (0.78–1.39) | 0.779       | 0.389       |                   |
| rs11771429| 7: 153271877 | T/C | All   | 15.3     | 0.85 (0.71–1.02) | 0.083       | 0.042       | XRCC2, ACTR3B, DPP6 |
|           |          |        | M     | 15.4     | 0.86 (0.70–1.06) | 0.157       | 0.079       |                   |
|           |          |        | F     | 14.2     | 0.81 (0.55–1.21) | 0.308       | 0.154       |                   |
| rs4523255 | 8: 8713038 | T/C   | All   | 39.5     | 1.14 (0.99–1.31) | 0.061       | 0.031       | CLDN23, MFHAS1, ERI1 |
|           |          |        | M     | 38.7     | 1.07 (0.91–1.25) | 0.420       | 0.210       |                   |
|           |          |        | F     | 45.7     | 1.40 (1.06–1.85) | 0.018       | 0.009       |                   |
| rs11789015| 9: 96716028 | G/A  | All   | 25.1     | 0.87 (0.75–1.02) | 0.088       | 0.044       | BARX1, PTPDC1, MILET7DHG |
|           |          |        | M     | 25.5     | 0.94 (0.79–1.13) | 0.533       | 0.267       |                   |
|           |          |        | F     | 22.0     | 0.67 (0.48–0.94) | 0.020       | 0.010       |                   |
| rs2669333 | 13: 63574196 | A/G | All   | 35.3     | 1.15 (1.00–1.33) | 0.050       | 0.025       | DIAPH3, TRDR3, PCDH20 |
|           |          |        | M     | 35.1     | 1.19 (1.01–1.41) | 0.036       | 0.018       |                   |
|           |          |        | F     | 36.8     | 1.04 (0.78–1.39) | 0.776       | 0.388       |                   |
| rs10144632| 14: 55242336 | G/A | All   | 23.2     | 0.87 (0.75–1.02) | 0.088       | 0.044       | SAMD4A, GCH1, WDHD1 |
|           |          |        | M     | 23.2     | 0.88 (0.73–1.05) | 0.156       | 0.078       |                   |
|           |          |        | F     | 23.2     | 0.86 (0.63–1.18) | 0.342       | 0.171       |                   |
| rs2895917 | 14: 102052775 | T/C | All   | 32.7     | 0.88 (0.76–1.02) | 0.086       | 0.043       | DIO3, PPP2R5C, DYN1C1H1 |
|           |          |        | M     | 33.0     | 0.91 (0.77–1.08) | 0.278       | 0.139       |                   |
|           |          |        | F     | 30.7     | 0.79 (0.59–1.06) | 0.120       | 0.060       |                   |
| rs9936833 | 16: 86403118 | C/T | All   | 39.4     | 1.13 (0.98–1.29) | 0.090       | 0.045       | FENDRR, FOXF1, MTHFSD |
|           |          |        | M     | 39.3     | 1.11 (0.95–1.30) | 0.178       | 0.089       |                   |
|           |          |        | F     | 40.6     | 1.16 (0.88–1.51) | 0.289       | 0.144       |                   |
| rs4800353 | 18: 19654137 | G/A | All   | 12.8     | 0.83 (0.69–1.01) | 0.067       | 0.034       | MB1, GATA6, CTAGE1 |
|           |          |        | M     | 12.9     | 0.84 (0.67–1.04) | 0.115       | 0.058       |                   |
|           |          |        | F     | 12.2     | 0.82 (0.54–1.25) | 0.351       | 0.175       |                   |

In total, 11 SNPs show EAC association when one-sided tested ($P_{1-d.f.} < 0.05$) with the same risk allele as observed in the previously published GWAS on EAC/Barrett’s esophagus [1, 6]. The results are given for the whole sample set (All) as well as for males (M) and females (F) separately (column “Group”).

1Chromosome (Chr) and position (Pos) according to hg19.
2First allele represents the minor allele.
3Minor allele frequency (MAF) is given for cases and controls.
4Odds ratio (OR) with 95% confidence interval (CI) indicating the genetic effect size is given for the minor allele.
5P-values using $n−1$ degrees of freedom (column “$P_{1-d.f.}$”) and $n−2$ degree of freedom (column “$P_{2-d.f.}$”) are shown, whereby P-values below 0.05 are highlighted in bold.
6Nearby genes are shown with the closest gene to the associated SNP given in bold.
In conclusion, we provide supportive evidence that genetic variants at FOXPI, BARXI, and FOXFI confer risk for the development of EAC. In addition, we found association with variants near XRCC2 and GATA6 that were strongly disease associated with the BEACON GWAS, although this was not genome-wide significant. Thus, both genes represent promising candidates for future EAC association studies on independent samples.

Acknowledgments

B. M.-M., I. G., M. V., and J. S. received support for this work from the Else Kröner Fresenius Stiftung (EKFS) (Individual grant 2013_A118). M. M. N. received support for this work from the Alfried Krupp von Bohlen und Halbach-Stiftung. The authors thank all patients and controls for participating to this study. In addition, we thank Prof. Bernd Pötzsch (Institute of Experimental Hematology and Transfusion Medicine, University of Bonn) for help with collecting DNA samples from anonymous blood donors. This work contains substantial parts of the doctoral theses of C.J.A., M.A. and S.H.

Conflict of Interest

None declared.

References

1. Levine, D. M., W. E. Ek, R. Zhang, X. Liu, L. Onstad, C. Sather, et al. 2013. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus. Nat. Genet. 45:1487–1493.

2. Gu, Y., S. Lin, J. L. Li, H. Nakagawa, Z. Chen, B. Jin, et al. 2012. Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene 31:469–479.

3. Woo, J., I. Miletich, B. M. Kim, P. T. Sharpe, and R. A. Shivdasani. 2011. Barx1-mediated inhibition of Wnt signaling in the mouse thoracic foregut controls tracheo-esophageal septation and epithelial differentiation. PLoS ONE 6:e22493.

4. Koon, H. B., G. C. Ippolito, A. H. Banham, and P. W. Tucker. 2007. FOXPI: a potential therapeutic target in cancer. Expert Opin Ther. Targets 11:955–965.

5. Shu, W., M. M. Lu, Y. Zhang, P. W. Tucker, D. Zhou, and E. E. Morrisey. 2007. Foxp2 and Foxp1 cooperatively regulate lung and esophagus development. Development 134:1991–2000.

6. Su, Z., L. J. Gay, A. Strange, C. Palles, G. Band, D. C. Whitman, et al. 2012. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett’s esophagus. Nat. Genet. 44:1131–1136.

7. Purcell, S., B. Neale, K. Todd-Brown, L. Thomas, M. A. Ferreira, D. Bender, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81:559–575.

8. Thacker, J. 2005. The RAD51 gene family, genetic instability and cancer. Cancer Lett. 219:125–135.

9. Alvarez, H., J. Opalinska, L. Zhou, D. Sohal, M. J. Fazzari, Y. Yu, et al. 2011. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet. 7:e1001356.

10. Kimchi, E. T., M. C. Posner, J. O. Park, T. E. Darga, M. Kocherginsky, T. Karrison, et al. 2005. Progression of Barrett’s metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 65:3146–3154.

11. Lin, L., A. J. Bass, W. W. Lockwood, Z. Wang, A. L. Silvers, D. G. Thomas, et al. 2012. Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma. Proc. Natl. Acad. Sci. USA 109:4251–4256.

Supporting Information

Additional supporting information may be found in the online version of this article:

Table S1. Esophageal adenocarcinoma (EAC) association findings in 1065 cases and 1019 controls at 88 SNP markers that showed disease association with P < 10^-4 in the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) GWAS sample (N = 85) [1] and at further three SNP markers at FOXFI that were implicated in Barrett’s esophagus [6]. In total, eight SNPs in the FOXFI region were tested for association (rs1490865 [16: 86387275] to rs4843376 [16: 86470082]). P-values below 0.05 are given in bold. The last column shows the odds ratios (OR) with 95% confidence intervals (CI) from the BEACON GWAS. The BEACON effect sizes are based on the combined meta-analysis (5564 patients, 10,118 controls). Only for the three additional SNP markers at FOXFI (highlighted with an asterisk), the effect sizes are given for the BEACON discovery sample (3928 patients, 3207 controls).

Figure S1. Forest plots of the five EAC-associated markers, namely rs2687201 (FOXPI), rs11771429 (XRCC2), rs11789015 (BARXI), rs9936833 (FOXFI), and rs4800353 (GATA6). The odds ratios (OR) and 95% confidence intervals (CI) from the replication study (Germany) and the previous GWAS (BEACON) were plotted. Except for the FOXFI marker rs9936833 (based on their discovery sample [3928 patients, 3207 controls]) the BEACON OR and CI are given for combined meta-analysis (5564 patients, 10,118 controls).